Medicus Pharma Ltd (MDCX) FinancialsMDCXFinancialMedicus Pharma Ltd

In the context of the broader market, MDCX competes directly with industry leaders such as PLUR and ADVB. With a market capitalization of $17.70M, it holds a leading position in the sector. When comparing efficiency, MDCX's gross margin of N/A stands against PLUR's 33.53% and ADVB's N/A. Such benchmarking helps identify whether Medicus Pharma Ltd is trading at a premium or discount relative to its financial performance.

Medicus Pharma has reported consistent net losses, with a net income of -11,684,427 USD in Q2 2026 and a negative EPS of -0.21. This indicates ongoing financial distress and lack of profitability.